Panacea Biotec's DENSTAR project officially launched on June 1, 2026, marking the beginning of a four-year initiative to advance the licensure of its DengiAll dengue vaccine across 54 African nations. The €11.1 million initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union and aligns with the EDCTP3 mission to combat Neglected Tropical Diseases (NTDs), including dengue fever. The project seeks to reduce the disease burden across Africa while positioning the company to address a population of over 1 billion people at risk of dengue infection, with the global risk estimated at nearly 3.9 billion people currently vulnerable to the disease. The initiative leverages the DengiAll vaccine platform, a tetravalent dengue vaccine targeting all four virus serotypes currently in late-stage development in India, to capitalize on the underserved dengue vaccine market in emerging economies.
The DENSTAR project will utilize Controlled Human Infection Models (CHIMs) to evaluate how well the vaccine protects against Dengue Virus serotype 4 (DENV-4)—a critical scientific gap that no vaccine has successfully addressed to date. Beyond laboratory testing, DENSTAR is heavily focused on building long-term scientific capacity within Africa by funding master's and doctoral training for local students and upgrading local clinical trial infrastructure. Prof. Ellis Owusu-Dabo, Pro-Vice-Chancellor of the Kwame Nkrumah University of Science and Technology (KNUST) and the scientific lead for the project, emphasized the local urgency: "Dengue infections are becoming more common in sub-Saharan Africa, driven primarily by climate change. The primary challenge of the DENSTAR project is to advance this live-attenuated vaccine through immunobridging and controlled infection models to enable its local licensure." The DENSTAR consortium will conduct Phase I/III clinical trials in healthy African adults and children to confirm the vaccine's safety and efficacy, with the project coordinated by Italy's non-profit Sclavo Vaccines Association.
Panacea Biotec reported 12% YoY revenue growth in its vaccine division in May 2026, demonstrating strong momentum in its biotech operations. The company successfully completed Phase 3 clinical trial enrollments for its Dengue vaccine in India in April, providing the foundational data required for the African licensing deal. According to market analysis, the partnership represents a calculated move into the Global South's health infrastructure, bypassing highly saturated Western markets in favor of high-volume, public-sector-driven demand, while providing sovereign guarantees for vaccine procurement through international advocacy groups.
The Dengue vaccine market is currently underserved, offering first-mover advantages in emerging economies as the disease becomes endemic in newer geographies. Panacea's DengiAll platform is positioned as one of the few live-attenuated candidates capable of providing long-term immunity, making it a viable candidate for large-scale public health programs. The DengiAll vaccine is a single-dose, cost-effective tetravalent vaccine that requires no prior blood testing before administration, making it uniquely scalable for large-scale, equitable deployment in lower- and middle-income countries. The partnership reduces regulatory hurdles for multi-country licensing while positioning the company as a primary supplier for high-demand, low-competition tropical medicine markets. However, challenges remain including potential competition from larger global pharmaceutical players entering the Dengue space and cold-chain logistics challenges in rural sub-Saharan Africa.
